Literature DB >> 4255688

Mithramycin for hypercalcemia of malignant disease.

T E Godfrey.   

Abstract

Mithramycin (Mithracin(R)) rapidly controlled the hypercalcemia of malignant disease in every patient. This control was temporary, and intermittent administration of the antibiotic was required.Hypercalcemia frequently responds to non-toxic maneuvers such as hydration and moderate doses of corticoids. Until the mechanism of action of Mithramycin in hypercalcemia is better understood, caution should be urged in its prolonged use for this purpose.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4255688      PMCID: PMC1517936     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  5 in total

1.  Hypercalcemia in neoplastic disease.

Authors:  W P L MYERS
Journal:  Cancer       Date:  1956 Nov-Dec       Impact factor: 6.860

2.  Mithramycin treatment of malignant hypercalcaemia.

Authors:  C R Edwards; G M Besser
Journal:  Br Med J       Date:  1968-07-20

3.  Mithramycin treatment of hypercalcemia.

Authors:  C P Perlia; N J Gubisch; J Wolter; D Edelberg; M M Dederick; S G Taylor
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

4.  Hypercalcemia of malignant disease.

Authors: 
Journal:  Calif Med       Date:  1967-07

5.  Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease.

Authors:  V Parsons; M Baum; M Self
Journal:  Br Med J       Date:  1967-02-25
  5 in total
  3 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  The pathophysiology and clinical aspects of hypercalcemic disorders.

Authors:  D B Lee; E T Zawada; C R Kleeman
Journal:  West J Med       Date:  1978-10

3.  Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis.

Authors:  P J Heyburn; J A Child; M Peacock
Journal:  J Clin Pathol       Date:  1981-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.